open access

Vol 15, No 4 (2008)
How to do
Published online: 2008-05-21
Submitted: 2013-01-14
Get Citation

New methods in laboratory diagnostics of dilated cardiomyopathy

Agata Bielecka-Dąbrowa, Magdalena Wierzbicka, Marek Dąbrowa, Aleksander Goch
Cardiol J 2008;15(4):388-395.

open access

Vol 15, No 4 (2008)
How to do
Published online: 2008-05-21
Submitted: 2013-01-14

Abstract

Dilated cardiomyopathy (DCM) is a multifactorial heart disease in which there is enlargement and systolic dysfunction of one or both ventricles. The exhaustion of compensatory mechanisms leads to symptoms of congestive heart failure, which is a significant problem in contemporary cardiology. DCM is still diagnosed using clinical assessment; echocardiography is necessary, and in some clinical situations we need hemodynamic assessment in order to identify the etiology and progression of heart disease. These tests are necessary for choice of treatment and qualification for heart transplant. Investigators are looking for new, valuable, additional parameters which could be of use in screening and heart disease progression assessment, and which may be helpful in the management and risk stratification of patients with DCM. These monitoring and prognostic tools in patients with chronic heart failure can be biomarkers, such as natriuretic peptides: BNP and NT-proBNP, cardiac troponins or inflammatory cytokines and their receptors. Moreover, there are ongoing research projects concerning persistently elevated uric acid, Ca-125 and osteopontin concentrations for the identification of patients with DCM, as well as adverse prognoses.

Abstract

Dilated cardiomyopathy (DCM) is a multifactorial heart disease in which there is enlargement and systolic dysfunction of one or both ventricles. The exhaustion of compensatory mechanisms leads to symptoms of congestive heart failure, which is a significant problem in contemporary cardiology. DCM is still diagnosed using clinical assessment; echocardiography is necessary, and in some clinical situations we need hemodynamic assessment in order to identify the etiology and progression of heart disease. These tests are necessary for choice of treatment and qualification for heart transplant. Investigators are looking for new, valuable, additional parameters which could be of use in screening and heart disease progression assessment, and which may be helpful in the management and risk stratification of patients with DCM. These monitoring and prognostic tools in patients with chronic heart failure can be biomarkers, such as natriuretic peptides: BNP and NT-proBNP, cardiac troponins or inflammatory cytokines and their receptors. Moreover, there are ongoing research projects concerning persistently elevated uric acid, Ca-125 and osteopontin concentrations for the identification of patients with DCM, as well as adverse prognoses.
Get Citation

Keywords

dilated cardiomyopathy; natriuretic peptides; cardiac troponins; inflammatory cytokines

About this article
Title

New methods in laboratory diagnostics of dilated cardiomyopathy

Journal

Cardiology Journal

Issue

Vol 15, No 4 (2008)

Pages

388-395

Published online

2008-05-21

Bibliographic record

Cardiol J 2008;15(4):388-395.

Keywords

dilated cardiomyopathy
natriuretic peptides
cardiac troponins
inflammatory cytokines

Authors

Agata Bielecka-Dąbrowa
Magdalena Wierzbicka
Marek Dąbrowa
Aleksander Goch

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl